SAN CARLOS, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present at the following conferences in April:
- American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29-April 3
Title: Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma
Authors: Viktoria Gontcharova et al.
Session Title: Late-Breaking Research: Immunology 1
Session Type: Late-Breaking Poster Session
Abstract Number: LB-069
Location: Georgia World Congress Center
Date/Time: Monday, April 1, from 8:00 a.m. - 12:00 p.m. EDT
- Jefferies 6th Annual IO Cell Therapy Summit in Boston, April 5
Location: Boston Harbor Hotel
Date/Time: Friday, April 5, at 10:35 a.m. EDT
- HC Wainwright Global Life Science Conference in London, April 7-9
Location: JW Marriott Grosvenor House London
Date/Time: Tuesday, April 9, at 9:50 a.m. BST
A live and archived webcast of the presentation will be available by visiting the Investors section of the Iovance Biotherapeutics website at http://ir.iovance.com.
- 2019 Cell & Gene Meeting on the Mediterranean in Barcelona, April 23-25
Location: Hotel Arts Barcelona
Date/Time: Wednesday, April 24, at 12:00 p.m. CEST
- 15th European Association of Dermato-Oncology (EADO) Congress in Paris, April 24-27
Title: Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocytes (LN-144, lifileucel) in previously treated metastatic melanoma patients (Encore presentation)
Location: Maison de la Chimie Conference Center
Date/Time: Thursday, April 25 at 2:07 p.m. CEST
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell therapy using tumor-infiltrating lymphocyte (TIL) technology that amplifies the body’s own immune response to eradicate solid tumors or attack blood cancers. The company is currently conducting the pivotal study innovaTIL-01 in patients with metastatic melanoma. In addition, the company’s TIL therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including cervical, head and neck, and non-small cell lung cancer. For more information, please visit www.iovance.com.
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”). We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. The forward-looking statements include, but are not limited to, risks and uncertainties relating to the success, timing, projected enrollment, manufacturing capabilities, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company-sponsored and collaborator-sponsored trials in both the U.S. and Europe), such as statements regarding the timing of initiation and completion of these trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the strength of Company’s product pipeline; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s manufacturing, license or development agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business, including, without limitation; the preliminary clinical results, including efficacy and safety results, from ongoing Phase 2 studies may not be reflected in the final analyses of these trials, including new cohorts within these trials, and may not be supportive of product approval; the FDA or other regulatory authorities may potentially delay the timing of their approval of, or other action with respect to, the Company’s product candidates; the Company’s ability to address FDA or other regulatory authority requirements relating to its clinical programs and registrational plans, such requirements including, but not limited to, clinical and safety requirements as well as manufacturing and control requirements; risks related to the Company’s accelerated FDA review designations; and the ability of the Company to manufacture its therapies using third party manufacturers. A further list and description of the Company’s risks, uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contacts:
Media Relations Contact:
Iovance Biotherapeutics, Inc.